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MitophagyLysine acetylation is a key post-translationalmodification known to regulate gene transcription, signal transduc-
tion, cellular transport and metabolism. Lysine deacetylases (KDACs), including classical KDACs (a.k.a. histone
deacetylases; HDACs) and sirtuins (SIRTs), are emerging therapeutic targets in neurodegeneration. Given the
strong link between abnormal mitochondrial dynamics and neurodegenerative disorders (e.g. in Alzheimer,
Parkinson and Huntington diseases), here we examine the evidence for KDAC-mediated regulation of mito-
chondrial biogenesis, fission–fusion, movement and mitophagy. Mitochondrial biogenesis regulation was
reported for SIRT1, SIRT3, and class IIa KDACs,mainly via PGC-1alphamodulation. SIRT1 or SIRT3 overexpression
rescuedmitochondrial density and fission–fusion balance in neurodegenerationmodels. Mitochondrial fission de-
creased with pan-classical-KDAC inhibitors and increased with nicotinamide (pan-sirtuin-inhibitor/activator
depending on concentration and NAD+ conversion). Mitochondrial movement increased with HDAC6 inhibition,
but this is not yet reported for the other tubulin deacetylase SIRT2. Inhibition of HDAC6 or SIRT2 was reported
neuroprotective. Mitophagy is assisted by the HDAC6 ubiquitin-binding and autophagosome–lysosome fusion
promoting activities, and was also associated with SIRT1 activation. In summary, KDACs can potentially modulate
multiple components of mitochondrial dynamics, however, several key points require clarification. The
SIRT1-biogenesis connection relies heavily in controversial caloric restriction (CR) regimes or CR-mimetic drugs,
and appears cell-type dependent, recommending caution before linking SIRT1 activation with general
neuroprotection. Future studies should clarifymitochondrial fission–fusion regulation by KDACs, and the interplay
betweenHDAC6 and SIRT1 inmitophagy. Also, further studies are required to ascertainwhether HDAC6 inhibition
to enhance mitochondrial trafficking does not compromise autophagy or clearance of misfolded proteins in neu-
rodegenerative disorders.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
1.1. An extended phenotype for lysine acetylation
Acetylation at the ε-amino group of lysines is a reversible post-
translational modification (PTM), crucial for regulating the function
of multiple proteins [1,2]. Lysine acetyltransferases (KATs) and lysine
deacetylases (KDACs) act in concert to modulate the acetylation sta-
tus of their targets. Since lysine acetylation prevents positive charges
from forming on the amino group, this PTM strongly influences pro-
tein electrostatic properties [3]. The functional consequences varyrestriction; DRG, dorsal root
istone acetyltransferase; HD,
sp90, heat shock protein 90;
se; Mff, mitochondrial fission
n factor 1; mtDNA, mitochon-
ic atrophy 1; PD, Parkinson's
slational modification; Tfam,
, Faculty of Pharmacy,University
rtugal. Tel.:+351 220 428 610;
rights reserved.with the relative position of specific lysine residues within the target
protein, andmaymanifest as increases as well as decreases in activity,
affinity, stability, or in protein–protein interaction [3,4].
Histones were the first substrates identified for eukaryotic
KATs and KDACs, explaining their common designation as histone
acetyltransferases (HATs) and deacetylases (HDACs), respectively
[1]. Histone acetylation strongly correlates with gene transcription,
likely by relaxing chromatin and facilitating access to the transcription
machinery.Moreover, acetylation of specific lysine residuesmay direct-
ly serve as recognition sites for transcription factors [5]. Still, when con-
sidering KDAC non-histone targets, particularly transcription factors, it
can no longer be generalized that increased acetylation stimulates tran-
scription. Indeed, acetylation of transcription factors may increase or
decrease their DNA binding affinity depending on whether the specific
acetylation sites fall directly adjacent or within the DNA-binding do-
main, respectively [4]. Thus, KATs' and KDACs' effects on acetylation
and transcription provide a versatile mechanism for coupling extracel-
lular signals with the genome.
Non-histone targets regulated by lysine acetylation are mostly
comprised by transcription factors, but the growing list also includes
other key cellular proteins, such as α-tubulin, importin α, heat shock
protein 90 (Hsp90), and cortactin, among others [3,6]. Thus, lysine
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also in signal transduction and cellular transport processes. Further,
lysine acetylation is a key metabolic regulatory signal, particularly at
the level of mitochondria [7].
KDACs in particular have received much attention not only for
their physiological roles, but also for their involvement in disease
states and, consequently, for being a therapeutic target [8]. In addi-
tion to cancer, neurodegenerative disorders are also under the scope
of possible therapy with drugs targeting KDACs [9,10]. Thus, consid-
ering the emerging role of abnormal mitochondrial dynamics in the
pathogenesis of neurodegenerative disorders [11], in this review we
examine the hypothesis that the extended phenotype of KDAC activ-
ity involves a modulation of mitochondrial dynamics that may have
therapeutic implications in neurodegeneration. We start by briefly
addressing key aspects of KDACs, followed by focused analyses on how
KDAC modulation impacts 4 divisions of mitochondrial dynamics: bio-
genesis, fission–fusion, movement, and mitophagy; and how such dy-
namics are affected in neurodegenerative diseases.
2. KDACs: classes and functions
The mammalian KDAC superfamily currently holds eighteen mem-
bers. A core division based on homology with yeast KDACs separates
‘classical HDACs’ (zinc-dependent, Rpd3/Hda1 homologues) from
‘sirtuins’ (NAD+-dependent, Sir2 homologues). Another division es-
tablishes four classes based on phylogenetic analysis and sequence
homology. Classes I, II and IV comprise classical HDACs (with class
II further divided into IIa and IIb), while class III comprises sirtuins
[12].
Class I KDACs (HDAC1, 2, 3, and 8) are predominantly nuclear and
widely expressed in most tissues, except for HDAC8 that is confined
to smooth muscle where it associates with α-actin and is essential for
contractility [13]. HDAC1 and 2 are highly homologous and act together
as the catalytic subunits of major transcriptional repressor complexes
such as Sin3, NuRD/NRD/Mi2, and CoREST [14]. This collaborative spirit
of KDACs [15] also applies to HDAC3, which is responsible for the
deacetylase activities associated with Class II KDACs, working together
in a repressor complex with SMRT/N-CoR [16]. Class II KDACs display
tissue-specific expression patterns, being highly expressed in the
brain, heart, and muscle. Class IIa contains HDAC4, 5, 7, and 9. While
full-length HDAC9 remains in the nucleus, HDAC4, 5, 7 and a splice var-
iant of HDAC9 (MITR) shuttle between the nucleus and cytosol. Phos-
phorylation and binding to 14-3-3 proteins anchor these HDACs in the
cytosol, whereas dephosphorylation releases them to return to the nu-
cleus [9]. Class IIb consists of HDAC6 and 10, both primarily cytosolic.
HDAC6 is unique in containing a C-terminal ubiquitin-binding domain
and two functional deacetylase domains. Cytosolic HDAC6 deacetylates
tubulin, cortactin and HSP90, regulating axonal trafficking, cell motility
and degradation of misfolded proteins. HDAC6 can also shuttle to the
nucleus to regulate transcription, with its activity and subcellular local-
ization being regulated by acetylation [17]. HDAC10 possesses a unique
leucine-rich domain, interacts with HDAC3, and represses transcription
when tethered to a promoter [18]. Class IV consists only of HDAC11, a
predominantly nuclear KDAC that regulates immune tolerance [19].
Sirtuins (Class III KDACs) comprise seven mammalian enzymes,
SIRT1-7. Their deacetylation reaction consumes the cofactor NAD+
while generating nicotinamide plus a mixture of 2′ and 3′-O-acetyl-
ADP-ribose [20]. SIRT1 is present in the nucleus, deacetylating histones
and several transcription factors. SIRT1 deacetylates and activates the
transcriptional co-activator PGC-1α, a master regulator ofmitochondri-
al biogenesis [21]. SIRT1 was reported predominantly cytosolic in the
adult brain [22], while PGC1-α may also reside in the cytosol being
directed to the nucleus by stimuli-associated PTMs [23,24]. SIRT2 is
primarily cytosolic but may also occur in the nucleus where it preferen-
tially deacetylates histone H4K16 [25]. SIRT2 shares α-tubulin
deacetylase activity with HDAC6 [26], and has been suggested as themain microtubule deacetylase in mature neurons [27], although it was
also reported that SIRT2 genetic reduction or ablation has no effect on
the acetylation ofα-tubulin or H4K16 inmouse brain [28]. Additionally,
SIRT2 is reported to deacetylate the transcription factor p65 in the cyto-
sol, thus regulating expression of NF-KB-dependent genes [29]. SIRT3, 4
and 5 are also called ‘mitochondrial sirtuins’ given their subcellular
location. SIRT3 is the main deacetylase in the mitochondria, where it
regulates oxidative phosphorylation, protein synthesis and multiple
metabolic pathways. The other two mitochondrial sirtuins show weak
deacetylase activity, with SIRT5 exhibiting pronounced demalonylase
and desuccinylase activity, and the primary activity of SIRT4 remaining
elusive [7]. SIRT6 is a nuclear histone H3K9 deacetylase with a key role
in telomere maintenance and DNA repair [30]. SIRT7 is a selective his-
tone H3K18 deacetylase [31] and an activator of RNA polymerase I tran-
scription [32].
3. The modulation of KDAC activity
Physiological modulation of KDACs may occur at multiple steps of
their life cycle, including transcription, pos-transcriptional and proteo-
lytic processing. Additionally, protein–protein interactions, co-factor
availability, and several PTMs allow dynamic activity control. Most
KDACs require integration in multi-protein complexes and nuclear local-
ization in order to repress transcription. Thus, the activity of such KDACs
predictably decreases upon interferencewith complex assembly/stability,
reduced availability of interacting proteins (e.g. N-CoR for HDAC3), or
enhanced nuclear export plus cytosolic retention (e.g. class II KDACs).
Conversely, for KDACs acting primarily in the cytosol (e.g. HDAC6 and
SIRT2), cytosolic retention can increase their activity [14].
PTM by phosphorylation may either increase (e.g. HDAC1) or de-
crease (e.g. HDAC8) class I enzymatic activity, while regulating class II
subcellular localization via binding to 14-3-3 proteins [14]. In turn, PTM
by acetylation of the catalytic domain and C-terminal region strong-
ly diminishes HDAC1 enzymatic activity [33] and, similarly, p300-
mediated SIRT2 acetylation reduces its deacetylase activity [34].
Also, ‘site B’-acetylation decreases HDAC6 tubulin- but not histone-
deacetylase activity (in vitro), although in situ histone acetylation
should decrease since the same PTM reduces HDAC6 nuclear import
[17]. Concerning co-factor availability, the NAD+:NADH ratio links
cellular metabolic status to class III KDACs' activity [14], whereas
zinc is critical for other KDACs' catalytic activity. Finally, while pro-
teolytic degradation of KDACs or their co-activators predictably
diminishes their activity, specific proteolytic processing may be re-
quired for full deacetylase activity (e.g. mitochondrial SIRT3 [35]).
Thus, multiple physiological processes modulate KDAC activity, and
some have already assisted drug development.
Pharmacological KDAC modulators are predominantly inhibitors,
with different structural requirements for acting on classical KDACs
vs. sirtuins. Few activators have been reported, except for SIRT1
where several presumed activators have been synthesized (inc.
SRT1720, SRT2183 and SRT1460), but there is now evidence that
these compounds and resveratrol are not direct SIRT1 activators [36], al-
beit recent data suggests that at least someof the physiological effects of
these type of compounds may occur by “assisted allosteric activation”
[37]. Most classical KDACs' inhibitors lack isoform-selectivity as they
act by chelating zinc in the catalytic domain. Differential interaction
with amino acid residues at the entry of the KDAC active site, and the
mimicking of natural substrates may account for isoform-selective in-
hibitors, but currently little is known about their structure–activity rela-
tionships [38–40]. Most sirtuin inhibitors prevent NAD+ from binding
the catalytic domain by blocking the required nicotinamide binding
site. Alternatively, some sirtuin inhibitors compete with the acetylated
peptide substrate for its binding site in the catalytic domain [20].
Examples of commonly used KDAC inhibitors of particular relevance
for this review are as follows. Pan-(classical)-KDAC inhibitors with
nanomolar IC50 include the hydroxamate derivatives trichostatin A
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valproate are class I and IIa inhibitors in the micro to millimolar range
[38]. Entinostat (MS-275) is anHDAC1-selective inhibitor [41], whereas
tubacin and tubastatin A are HDAC6-selective inhibitors, respectively,
with ~350- and 1000-fold selectivity over HDAC1 [42]. Concerning
sirtuins, nicotinamide is often used as a pan-sirtuin inhibitor, whereas
EX527 and AGK2 are described as selective SIRT1 and SIRT2 inhibitors,
respectively [20].
4. Biogenesis
Mitochondria are continuously renewed by the physiological
equilibrium between biological generation (biogenesis) and selec-
tive degradation through autophagy (mitophagy). Increasing the cellular
mitochondrial mass is biologically expensive and a long-term adaptive
response. As such, transient energy demands are met by changes in ex-
pression of subsets of genes, regulators, or increases in mitochondrial
function. Physiological states such as endurance training, caloric restric-
tion, and long-term cold exposure (leading to adaptive thermogenesis)
are reported to promote mitochondrial biogenesis [43,44].
A complex network of nuclear and mitochondrial transcription
factors orchestrate mitochondrial biogenesis, a process in which the
PGC-1 family of transcriptional coactivators plays master regulatory
roles. PGC-1 coactivators integrate signals and coordinate biological
responses allowing cellular adaptation to changes in energy demand,
including increases inmitochondrial biogenesis, respiration andmetabo-
lism [45]. PGC-1α coactivates nuclear respiratory factors (NRFs), which
control expression of nuclear-encoded mitochondrial structural proteins
[46]. The resulting preproteinsmust be imported, processed and correctly
assembled in mitochondria, a complex process involving finely tuned
posttranscriptional mechanisms and the target of rapamycin (TOR) sig-
naling pathway [47]. PGC-1α-coactivated NRFs also regulate expression
of mitochondrial transcription factor A (Tfam), a nuclear-encoded tran-
scription factor crucial for replication, transcription, and maintenance of
mitochondrial DNA (mtDNA) [48].
4.1. KDACs and mitochondrial biogenesis
The link between KDACs and mitochondrial biogenesis stems pri-
marily from the modulation of PGC-1α by transcriptional or posttrans-
lationalmechanisms (Fig. 1; Table 1). PGC-1α transcription is promoted
by myocyte-enhancer factor-2 (MEF2) and diminished by class IIa
KDACs that repress MEF2 activity. Both class IIa KDACs and MEF2 tran-
scription factors are highly expressed in muscle and brain, and phos-
phorylation of these KDACs promotes their nuclear export, releasing
MEF2 to activate PGC-1α transcription [49]. Consistently, pan-KDAC in-
hibitors (trichostatin A and valproate) upregulated PGC-1α in neuro-
blastoma cells [50]. Concerning posttranslational mechanisms, PGC-1α
acetylation by the GCN5 acetyltransferase reduces its transcriptional ac-
tivity [51], whereas deacetylation by SIRT1 activates PGC-1α [21]. Inter-
estingly, SIRT1 converges with AMP-activated kinase (AMPK) to activate
PGC-1α; AMPK increases levels of the SIRT1 cofactor NAD+ [52] and ac-
tivates PGC-1α by phosphorylation [53]. Further, these posttranslational
modifications of PGC-1α activity also promote its own transcription via
an autoregulatory feedforward loop [54].
The relationship between SIRT1 and mitochondrial biogenesis has
been mostly explored in the context of caloric restriction (CR) — a re-
gime reportedly capable of extending life span by inducing SIRT1 ex-
pression [55]. However, studies reporting increased mitochondrial
biogenesis following CR [56–58] were challenged by a recent study
showing no increases in mitochondrial structural proteins in several
rat tissues including the brain [59]. Notwithstanding, CR lacks the se-
lectivity required to scrutinize the pathways linking SIRT1 and mito-
chondrial biogenesis. Alternatively, compounds designated as SIRT1
activators or “CR mimetic drugs” have been tested and reported to
improve mitochondrial function and enhance mitochondrial biogenesisand function [60–62]. Still, there is now evidence that such compounds
(inc. resveratrol, SRT1720, SRT2183, and SRT1460) do not directly acti-
vate SIRT1 [36], but see also the recently suggested “assisted allosteric ac-
tivation” in [37]. Attention has thus turned to AMPK, the SIRT1 partner in
activating PGC-1α [52]. Some authors argue that AMPK is upstream of
SIRT1 in the cascade of resveratrol metabolic effects, including mito-
chondrial biogenesis. Accordingly, AMPK-deficient mice presented a
faulty response to resveratrol and AMPK was considered the main res-
veratrol target [63]. More indirectly, resveratrol was reported to inhibit
cAMP-degrading phosphodiasterases, increasing cAMP levels and ignit-
ing a cascade that activates AMPK [64]. In both studies, upstreamAMPK
activation led to NAD+ increases explaining indirect SIRT1 activation
by resveratrol [63,64]. In contrast, a recent study positions AMPK down-
stream of SIRT1, provided that resveratrol is used in “moderate” doses
[65]. In that study, authors argue that while high doses of resveratrol
may activate AMPK directly, moderate doses increase mitochondri-
al biogenesis in a SIRT1-dependent manner, upstream of AMPK ac-
tivation. Thus, resveratrol indirect activation of AMPK was reported
SIRT1-dependent, via deacetylation of the AMPK kinase LKB1. Sig-
nificantly, both high and moderate doses of resveratrol failed to in-
crease mitochondrial biogenesis in SIRT1 knockouts [65].
4.2. Neuronal mitochondrial biogenesis and KDAC modulation
The effects of KDACmodulation onneuronalmitochondrial biogenesis
have been scarcely explored (the wealth of current data on these signal-
ing pathways pertains to non-neuronal cells). As far as we could find,
KDAC activation in neurons (or neuroblastoma cells) has been tested
only for SIRT1, by means of overexpression or using compounds such as
resveratrol (with doubtful SIRT1 specificity [36]). Conversely, the effects
of KDAC inhibition have been tested using SIRT1 deletion, the SIRT1 in-
hibitor EX-527, and pan-KDAC inhibitors. Such data are reviewed
below, identifying the models and with the proviso that neuroblastoma
cell lines can behave quite differently from post-mitotic neurons.
In neuroblastoma cells (Neuro2a), resveratrol was reported to
increase mitochondrial biogenesis markers through AMPK activation
[66]. Authors excluded SIRT1 involvement in AMPK activation in neuro-
blastoma or primary neurons since neither SIRT1 inhibitors (sirtinol,
splitomycin, and nicotinamide) nor SIRT1 deletion attenuated AMPK
activation. Interestingly, their study suggests that resveratrol effects
are neuron-type-dependent. According to their results, AMPK phos-
phorylation in dorsal root ganglion (DRG) neurons is primarily depen-
dent on LBK1 activity, whereas in cortical neurons it also requires
CamKKB [66]. Still, their study suggests that LKB1 activity is SIRT1 inde-
pendent,which is compatiblewith some studies [64], but contrastswith
others reporting SIRT1-dependence [65,67]. Such diverse findings
might be explained by cell-type-dependent variations on these signal-
ing pathways. Still, regardless of whether resveratrol has multiple tar-
gets that might modulate mitochondrial biogenesis, it is important to
verify if directly targeting SIRT1 activity suffices for altering mitochon-
drial biogenesis in neurons.
In primary cortical neurons, SIRT1 overexpression or GCN5
acetyltransferase silencing increasedmitochondrial density in cell bodies
and axons [68]. Further, increased mitochondrial biogenesis by SIRT1
was critically dependent on PGC-1α, but independent from AMPK.
Also, authors showed that SIRT1 effects resulted from deacetylating
PGC-1α and increasing its transcriptional activity [68].
In vivo SIRT1 inhibition (with EX-527) increased mitochondrial den-
sity in hypothalamic proopiomelanocortin (POMC) neurons, without af-
fecting indexes of mitochondrial morphology [69]. This was interpreted
as an adaptive response to decreased inhibitory tone on POMC neu-
rons [69]. Conceivably, the heightened activity of uninhibited POMC
neurons consumes ATP, increasing the AMP:ATP ratio and activating
AMPK-dependentmitochondrial biogenesis via PGC-1αphosphorylation.
Taken together, these findings suggest that increased SIRT1 activity
promotes neuronal mitochondrial biogenesis [68], but this may also
Fig. 1.Modulation of mitochondrial dynamics by KDACs. Biogenesis: Involvement of classical KDACs and sirtuins on mitochondrial biogenesis pathways. Movement: Role of tubulin
deacetylases HDAC6 and SIRT2 in regulating mitochondrial trafficking. Also, nuclear export and trafficking impairment by HDAC1 following injury. Fission–Fusion: Mediators of
mitochondrial fission and fusion, and putative roles of KDAC modulation.Mitophagy: HDAC6 recognizing ubiquitinated mitochondria, assisting transport and promoting autophagosome–
lysosome fusion via cortactin deacetylation together with SIRT1.
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hibition, at least in specific neuronal populations [69]. Significantly,
pan-inhibition of KDACs (trichostatin A and valproate) in neuroblas-
toma cells was reported to upregulate PGC-1α [50], and thus may
evoke mitochondrial biogenesis. Clearly, more studies are required
to elucidate how the AMPK-SIRT1-PGC-1α axis, and other KDACs
work in neurons to modulate mitochondrial biogenesis. Current ev-
idence suggests that SIRT1 activity and signaling are highly cell-type
dependent, thus advising caution before establishing links between
SIRT1 activation and general neuroprotection.
4.3. Mitochondrial biogenesis in neurodegeneration
Multiple neurodegenerative disorders have been associated with
abnormal mitochondrial biogenesis. Decreases in PGC-1α levels were
reported in the context of Huntington (HD), Alzheimer (AD), and
Parkinson's (PD) diseases as well as in spinal and bulbar muscular atro-
phy, whereas PGC-1α overexpression was protective in several in vitro
and in vivo diseasemodels [70], although a recent study evidenced that
sustained PGC-1α overexpression was deleterious to dopaminergic
neurons in vivo [71]. Mitochondria number was found decreased in
HD patients' brains, together with decreased levels of PGC-1α, Tfamand mitochondrial cytochrome c oxidase subunit II [72]. Moreover,
PGC-1α null mice presented neurodegenerative lesions predominantly
in the striatum [73], a particularly vulnerable region in HD [74]. Mito-
chondria number was also decreased in primary neurons cultured
from AD mice [75] and in AD patients' brains [76] together with de-
creased expression of PGC-1α, NRF1, NRF2a/2b and Tfam [77]. In PD pa-
tients, both PGC-1α and NRF-1 mRNA were decreased in the substantia
nigra and striatum [78]. Furthermore, some PGC-1α polymorphisms
have been tentatively associated with risk or age of onset of PD [79]
and HD [80–82], although population stratification may have influenced
result interpretation [83].
PGC-1α thus represents an interesting target to rescuemitochondrial
biogenesis in neurodegeneration models, yet relatively unexplored in
what concerns KDAC modulation. Significantly, one study reported that
SIRT1 overexpression restoredmitochondrial density and increased sur-
vival both in PD and HD neuronal models, respectively, expressing A53T
α-synuclein and 120Q huntingtin [68]. Further studies are required to
clarify SIRT1 and other KDACs' potential as mitochondrial biogenesis
modulators in neurons and more specifically in neurodegenerative dis-
order models.
Recently, another sirtuin (SIRT3) was reported to stimulate mito-
chondrial biogenesis [84] (Fig. 1). Silencing of the mitochondrial sirtuin
Table 1
KDACs and mitochondrial biogenesis.
KDAC isoform Model Activity modulation method Main findings Comments Ref.
10 μM EX-527 (24h) Decreased mtDNA
shSIRT1
Decreased mtDNA. Unaltered PGC-1α, NRF-1, NRF-2, COX5β
and ATP5αmRNA.
SIRT1-Tg mice skeletal muscle Constitutive SIRT1 expression Increased mtDNA. Increased PGC-1α, NRF-1 and Tfam mRNA.
Low SIRT1 expression
Unaltered  mitochondria number per cardiomyocyte area. 
Unaltered PGC-1α, NRF-1 and Tfam mRNA.
Moderate SIRT1 expression 40% decrease in NRF-1 mRNA.
High SIRT1 expression 50% decrease in NRF-1 mRNA.
10 μM SRT1720 (24h) 
Increased PGC-1α expression. 50% decrease in aceylated-PGC-
1α. Unaltered PGC-1α mRNA levels. Increased (3.5x) mtDNA 
content. 
100 μM Nicotinamide 
Unaltered mtDNA content. Nicotinamide pre-treatment 
prevents SRT1720-induced mtDNA content increase.
SIRT1 Mouse POMC neurons 1.5 nmol/mouse EX-527 (i.c.v) Increased mitochondrial density and area in the soma.
SIRT1 blocked the recruitment of inhibitory synapses 
onto POMC neurons, increasing their activity. Suggests 
that SIRT1 activation in NPY/Agrp neurons is essential 
for physiological adaptation to negative energy 
balance.
[69]
SIRT1 overexpression
Increased mitochondrial density. SIRT1 increased PGC-1α 
transcriptional activity but not PGC-1α transcription. 
SIRT1G261A expressiont Unaltered mitochondrial density.
Cortical neurons expressing mutantα-synuclein 
Cortical neurons expressing mutant huntingtin
SIRT1 C2C12 myotubes shSIRT1 Unaltered PGC-1α protein levels.
Reports that resveratrol benefits mice with diet-
induced obesity; SIRT1 activation by resveratrol and 
SIRT1-dependent PGC-1α activation.
[60]
SIRT3 overexpression Decreased mitochondrial protein synthesis
SIRT3N87A expression Unaltered mitochondrial protein synthesis
shSIRT3 Increased mitochondrial protein synthesis
Liver mitochondria from SIRT3-/- mice SIRT3-/-
Bovine liver mitochondria Isolation with 10 mM Nicotinamide
SIRT3 overexpression mtDNA copy number increased by 1.7-fold
shSIRT3 Unaltered mtDNA copy number
Class I, IIa and IIb 0.4 μM TSA (16-18h) 
Class I and IIa 10 mM Valproate (16-18h)
Mice with doxycycline (DOX)-inducible cardiac-
specific HDAC5S/A signal-resistant mutant
(+) vs. (-) DOX: represses vs. induces 
HDAC5S/A transcription
(+) DOX decreased mitochondria number. (-)DOX decreased 
PGC-1α expression
HDAC5S/A expression Prevents PGC-1α promoter activation by MEF2
HDAC3 HDAC3 overexpression Does not alter PGC-1α promoter activation by MEF2
[65]
[186]
[61]
[68]
[85]
[50]
[49]
[84]
SIRT1
C2C12 myoblasts Suggests that SIRT1 Is required for AMPK activation and 
the beneficial efects of resveratrol on mitochondrial 
function, including enhanced mitochondrial biogenesis.
SIRT1 Mice with heart-specific SIRT1 overexpression
Reports that constitutive SIRT1 overexpression in the 
heart impairs mitochondria and reduces cardiac 
function.
Proposes SIRT3 as a PGC-1α downstream target gene 
and a regulator of PGC-1α effects on mitochondrial 
metabolism. SIRT3 suggested to suppress ROS levels 
and regulate mitochondrial biogenesis.
SIRT1 Rabbit primary renal proximal tubule cells
Suggests that SIRT1 activation induces mitochondrial 
biogenesis through an AMPK-independent pathway, 
protecting mitochondria and renal proximal tubule cells 
against acute oxidant injury.
SIRT1
Rat primary cortical neurons Reports the regulation of mitochondrial density in 
neurons by PGC-1α and PGC-1β, and that increased 
PGC-1α or SIRT1 expression protects against mutantα- 
synuclein or huntingtin.Reverts mitochondrial density decrease.
Identifies HDAC5 as an indirect PGC-1α transcription 
regulator via MEF2 activity control.
COS cells
SIRT3
C2C12 cells
Proposes that matrix SIRT3 deacetylates mitochondrial 
ribossomes controlling their activity.
SIRT3 C2C12 myotubes
Increased PGC-1α mRNA
Reports that PGC-1α overexpression protects SH-SY5Y 
cells and that HDAC inhibition upregulates PGC-1α.
HDAC5
SH-SY5Y neuroblastoma
SIRT1 overexpression
Higher translational activity of mitochondrial ribosomes
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genesis, and authors proposed that SIRT3 might regulate NRF-1
and Tfam activities [84]. Interestingly, another study reported that
SIRT3 deacetylates the ribosomal protein MRPL10 down-regulating
the synthesis of mitochondrial proteins. Consistently, SIRT3 knockout
mice presented increased expression of mitochondrially-encoded com-
ponents of oxidative phosphorylation [85]. Thus, whether SIRT3 pos-
itively or negatively modulates mitochondrial biogenesis remains
uncertain and, as far as we could find, unaddressed in neurons. Nev-
ertheless, it was recently shown that expression of either SIRT3 or
PGC-1α was neuroprotective in an amyotrophic lateral sclerosis
model, rescuing defects in mitochondrial dynamics [86], specifically
fission–fusion dynamics, which is the subject of the next section.
5. Fission–fusion
Mitochondria are a highly dynamic organelle population that changes
size and morphology by fusing together or dividing through fission.
Mitochondrial fusion enables the exchange of mtDNA and other
matrix components between mitochondria, rendering protection
against mtDNA mutations by allowing functional complementation
and thus maintaining a healthy oxidative phosphorylation system
[87,88]. Mitochondrial fission permits mitochondrial separation to
daughter cells during mitosis [89], allows segregation of dysfunc-
tional mitochondria to be targeted for mitophagy [90], and enables
the mitochondrial size and shape adaptations required for distribu-
tion in neuronal ramifications [91–93] (Fig. 1).
Mitochondrial fusion involves merging of the outer as well the
inner mitochondrial membranes, a coordinated process assisted by
different proteins [94]. Mitofusins (Mfn1 and Mfn2) promote outer
membrane fusion. These are highly homologous GTPases anchored
to the outer membrane and able to form homo- or hetero-protein com-
plexes [95], which allows mitochondrial tethering and fusion in a GTP
hydrolysis-dependent manner [96]. Inner membrane fusion depends on
optic atrophy 1 (OPA1), a GTPase protein also involved in maintaining/
remodeling cristae structure [97]. OPA1 operates similarly tomitofusins,
forming trans-complexes that lead to inner membrane fusion [98,99].
Mutations in Mfn2 cause Charcot–Marie–Tooth type 2A neuropathy
[100], whereasmutations in OPA1 cause autosomal dominant optic atro-
phy [101].
Mitochondrial fission in mammals is mediated by Drp1, a cytosolic
dynamin-related protein that is recruited to specific sites on the mito-
chondrial outer membrane and homo-oligomerizes, forming spiral
chains aroundmitochondria that constrict and ultimately scission mi-
tochondria in a GTP hydrolysis-dependent manner [102]. Significant-
ly, a dominant-negative mutation in Drp1 was reported in a newborn
with lethal neurodevelopmental abnormalities, exhibiting defects in
both mitochondrial and peroxisomal fission [103]. Consistently, Drp1
knockout causes abnormal brain development and embryonic death
in mice [92]. In yeast, Drp1 attaches to mitochondria by binding to
Fis1, a protein anchored to themitochondrial outermembrane. Inmam-
mals, however, other mitochondrial outer membrane proteins seem to
take over the Drp1 receptor role. Thus, mitochondrial fission factor
(Mff) was proposed as an essential factor for Drp1 recruitment, mediat-
ing fission independently from Fis1 [104]. Alternatively, mitochondrial
elongation factor 1 (MIEF1) [105], also identified as MiD49/51 [106],
can bind Drp1 and inhibit its GTP hydrolysis thus promoting fusion in-
stead of fission [107]. According to such model, Fis1 could promote
fission by sequestering MIEF1 and consequently unblocking Drp1 GTP
hydrolysis [105,107]. It is also possible that MIEF1 levels determine the
outcome, with elevated levels compromising selective Drp1 recruitment
to constriction sites, leading to its uniform distribution, preventing for-
mation of active scission complexes, and thus causing fusion instead of
fission [106]. Recently, Fis1was also proposed tomodulatemitochondri-
al morphology by recruiting the GTPase regulator protein TBC1D15, in a
Drp1-independent manner [108]. Thus, while both Drp1 and Fis1 seemto be key players in the regulation of mammalianmitochondrial dynam-
ics, whether and how they interplay remains to be unraveled.
5.1. KDACs and mitochondrial fission–fusion
Treatmentwith different KDAC inhibitors, including pan-, class I- and
isoform-selective inhibitors, inducedmitochondrial elongation in several
cell lines, including primary cultures, untransformed and cancer cell lines
[109]. Mitochondrial elongation occurred at both subtoxic and toxic con-
centrations, indicating that mitochondrial structural integrity per se was
not sufficient to protect cells against apoptotic stimuli. Further, the KDAC
inhibitors increased histone H3 acetylation, decreased Fis1 expression
levels, and decreased Drp1 recruitment to the mitochondria, without al-
tering the levels or acetylation status of the Drp1, Mff, Mfn1, Mfn2, and
OPA1 proteins [109]. These findings suggest that mitochondrial elonga-
tion by KDAC inhibitors resulted from the down-regulation of an essen-
tial mitochondrial fission mediator, Fis1, which was recently reported as
a mitochondrial fusion preventer via MIEF1 sequestration [105] (Fig. 1).
The concept that KDAC inhibitors decrease Fis1 levels may, at first,
seem unexpected given the general view that increased histone acetyla-
tion should promote transcription and, consequently, protein expres-
sion. Still, KDACs act on multiple non-histone targets, and changes in
the lysine acetylation status of transcription factors may either increase
or decrease their activity [4]. Also, KDAC inhibition has been shown to
down-regulate proteins by promoting their ubiquitin-dependent degra-
dation; e.g. DNA methyltransferase 1 (DNMT1) is polyubiquitinated
when KDAC inhibition hyperacetylates the Hsp90 chaperone preventing
its interaction with DNMT1 [110]. Thus, the reported decrease in Fis1
protein levels [109] might partly result from increased degradation,
and not necessarily from decreased transcription.
Increased mitochondrial fragmentation was reported for human
fibroblasts treated with nicotinamide [111]. Similar findings were
reported for SIRT1 activators, SRT1720 or fisetin, only when SIRT1
expression was intact [112]. Nicotinamide, one of the final products
of sirtuin-catalyzed deacetylation, is frequently used as a sirtuin in-
hibitor. However, it is reported to activate SIRT1when used in lower con-
centrations (5 mM), since nicotinamide readily converts into the SIRT1
cofactor NAD+ via the “NAD+ salvage pathway” [112]. Togetherwith in-
creased mitochondrial fragmentation, nicotinamide reduced the mito-
chondrial mass, increased mitochondrial membrane potential (Δψm),
and evoked a time-dependent increase in the levels of Drp1, Fis1 and
Mfn1. Thus, it was suggested that nicotinamide enhances mitochondrial
quality, with optimized levels of fission and fusion mediators facilitating
separation of defectivemitochondria formitophagy [111], this beingme-
diated by high NAD+:gNADH ratio and SIRT1 activation [112] (Fig. 1;
Table 2).
5.2. Neuronal mitochondrial fission–fusion and KDAC modulation
In spite of accumulating evidence for abnormalmitochondrial fission–
fusion dynamics in neurodegenerative diseases, there is limited data
on the regulation of neuronal mitochondrial morphology by KDAC mod-
ulation. Impaired mitochondrial fusion and smaller mitochondrial size
were recently reported for motor neurons expressing mutant superoxide
dismutase (SOD1) [113]. Accordingly, previous studies reported de-
creased mitochondrial length and disrupted mitochondrial distribu-
tion in cell and animal models of amyotrophic lateral sclerosis (ALS)
[114–116], which may stem from decreased OPA1 and increased
Drp1 levels inmitochondria [117]. Concerning KDACs in this context,
it was recently reported that SIRT3 overexpression rescued mito-
chondrial fragmentation in cortical neurons expressing SOD1G93A
[86]. While the mechanisms by which SIRT3 corrects mitochondrial
morphology remain uncertain, it was proposed that SIRT3 deacetylation
of cyclophilin D and resulting inhibition of mitochondrial permeability
transition may play a neuroprotective role [86].
Table 2
KDACs and mitochondrial fission–fusion.
KDAC isoform Model Activity Modulation Method Main Findings Comments Ref.
5 mM Nicotinamide Mitochondrial fragmentation and decreased mitochondrial content.
20 mM Nicotinamide Increased mitochondrial content.
1 μM - 5 mM NAD+ 
Resveratrol
10 μM Fisetin + siSIRT1 
160 nM SRT1720 + siSIRT1
SIRT1 Mouse POMC neurons 1.5 nmol/mouse EX-527 (i.c.v.)
Unaltered mitochondrial morphology. Unaltered soma 
mitochondria cross-sectional area and circularity.
SIRT1 blocked recruitment of inhibitory synapses onto 
POMC neurons, increasing their activity. Suggests that 
SIRT1 activation in NPY/Agrp neurons is essential for 
the physiological adaptations to negative energy 
balance.
[69]
SIRT1 Normal human fibroblasts 5 mM Nicotinamide
Induced mitochondrial fragmentation and reduced 
mitochondrial mass. Increased Drp1, Fis1 and Mfn1 expression 
levels.
Proposes that nicotinamide optimises mitochondrial 
quality control by promoting fragmentation and 
mitophagy.
[111]
SIRT2-3 Spinal cord tissue from SOD1G93A  mice
SIRT2 Fluorimetric Drug Discovery Kit 
(Enzo Life Science) - buffer containing 
10 mM nicotinamide and 1 μM TSA  
Decreased deacetylase activity
SIRT3 Mice cortical neurons expressing SOD1G93A SIRT3 overexpression SIRT3 expression rescued mitochondrial fragmentation
Class I, IIa and IIb Hep3B (hepatoma cell line)
8 μM SAHA (48h) - induces 50% cell  
death
Mitochondrial elongation. Decreased Fis1 expression and Drp1 
translocation to the mitochondria. Unaltered Drp1, Mff, Mfn1, 
Mfn2 and OPA1 expression. Increased H2A, H3 and H4 
acetylation. Unaltered Drp1, Fis1, Mfn1 and OPA1 acetylation.
Mitochondrial elongation. Increased H3 acetylation.
Primary rat articular chondrocytes
Class I, IIa and IIb 0.4 μM TSA (12h)
2 μM Tubacin or 1 μM Tubastatin A (12h)  
Class I, IIa and IIb 10 mg/kg TSA (3 weeks in vivo) Unaltered mitochondria number
HDAC6 25 mg/kg Tubastatin A (3 weeks in vivo) Increased mitochondria number
HDAC6 Rat primary hippocampal neurons 5 μM Tubastatin A (3h) Unaltered mitochondria length or density
Reports that HDAC6 inhibition increases α-tubulin  
acetylation, preventing axonal mitochondrial trafficking 
impairment and disrupted morphology caused by Aβ1-42. [157]
Class I, IIa and IIb 0.4 μM TSA (16-18h) 
Class I and IIa 10 mM Valproate (16-18h)
HDAC5
Mice with doxycycline (DOX)-inducible cardiac-
specific HDAC5S/A signal-resistant mutant
(+)DOX - represses HDAC5S/A 
transcription (-)DOX - induces 
HDAC5S/A transcription
(-)DOX mitochondria were swollen with disrupted cristae 
Identifies HDAC5 as an indirect PGC-1a transcription 
regulator via MEF2 activity control.
[49]
[109]
[158]
[50]
[86]
[112]
[186]SIRT1 Mice with heart-specific SIRT1 overexpression Unaltered mitochondrial size
SIRT1 Normal human fibroblasts
Reports that 5mM nicotinamide converts in NAD+ 
through the "NAD+ salvage pathway", increasing the 
NAD+/NADH ratio and activating SIRT1, which leads to 
mitochondrial fragmentation and autophagy activation.Mitochondrial fragmentation and decreased mitochondrial 
content rescued by SIRT1 KO.
SH-SY5Y neuroblastoma Unaltered Mfn1 and Mfn2 gene expression
Reports that PGC-1α overexpression protects SH-SY5Y
cells and that HDAC inhibition upregulates PGC-1α.
Class I, IIa and IIb 
(TSA). Class I and 
IIa (VPA and 
NaBut), Class I 
(Trapoxin A), 
HDAC2, 3 and 8 
(Apicidin A), 
HDAC1 (MS-275)  
40 μM TSA; 30 mM VPA; 10 mM  
Sodium Butyrate; 10 nM Trapoxin A; 1 
ug Apicidin A; 15 μM MS-275 (48h) -
These concentrations induce apoptosis 
in ~50% cells after 48h
Mitochondrial elongation
DRG neurons from 10 months-old HSPB1S135F 
mice Mutant HSPB1 mice presented impaired mitochondria 
movement and decreased acetylated-tubulin in 
peripheral nerves. HDAC6 inhibition reverted the 
phenotype.
HDAC6
DRG neurons from 8 months-old HSPB1S135F 
mice
Reports that constitutive SIRT1 overexpression in the 
heart impairs mitochondria and reduces cardiac 
function.
Cancer cell lines (Hep3B, T98G, U118MG, 
U87MG, U373MG, PC3, ZR-75-1, and KAT18)
ARPE19 (retinal pigment epithelium cell line)
SOD1G93A mutation increases mitochondria 
fragmentation and impairs movement. Non-functional 
Drp1 decreases mitochondria fragmentation, restores 
movement and diminishes cell death in SODG93A motor
neurons. SIRT3 or PGC-1α transfection rescued 
mitochondrial fragmentation  improving neuronal 
Reports that small molecule KDAC inhibition elongates 
mitochondria even at concentrations causing 50% cell 
death. Decreased Fis1 expression might be involved.
Mitochondrial fragmentation and decreased mitochondrial 
content.
Increased mitochondria number
Low, moderate, and high SIRT1 
expression
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Abnormal mitochondrial fission–fusion dynamics, with disequilib-
rium towards fission has been described for multiple neurodegenera-
tive disorders. In the AD brain, reductions in Mfn1, Mfn2, OPA1 and
Drp1 levels were reported together with increased Fis1 levels [118]. In
the context of PD, mutations in the serine/threonine kinase PINK1 or in
the E3 ubiquitin ligase Parkin are major causes of familial PD, and these
twoproteins seem to functionally interact in the control ofmitochondrial
dynamics, albeit not in a simple linear pathway [119]. Mutant PINK1 is
reported to promotemitochondrial fission or decrease fusion inmamma-
lian cells. Possiblemechanisms are thatmutant PINK1 promotes Drp1mi-
tochondrial translocation, and interfereswithwild-type PINK1 pro-fusion
effect of increasing the fusion/fission protein ratio [120]. Parkin acts
downstream of PINK1, thus mutations in either protein may promote
fission by reducing wild-type Parkin-promoted degradation of Drp1
[121] or Fis1 [120].
HD is also associated with increased mitochondrial fission, with a
study in patients' brain samples reporting increased expression of Drp1
and Fis1, and decreased expression ofMfn1, Mfn2, and OPA1 [122]. This
contrasts with findings in several HD cell lines reporting no relevant
changes in pro-fission or pro-fusion protein levels [123]. Alternatively,
the pro-fission phenotype observed in HD cells may stem from abnor-
mal Ca2+ homeostasis activating calcineurin, which dephosphorylates
Drp1 promoting its translocation ontomitochondria [123–125]. Consis-
tently, a recent study proposes that phosphorylation hinders Drp1 olig-
omerization, reducing its recruitment by Mff or preventing completion
of fission-competent Drp1 spirals, thus inhibiting mitochondrial fission
[126]. Alternatively, increased mitochondrial fission in HD may stem
from an abnormal interaction between mutant huntingtin and Drp1,
which is proposed to increase Drp1 enzymatic activity and thus pro-
motes mitochondrial fragmentation [127,128]. Similarly, in AD con-
text, beta amyloid was reported to abnormally interact with Drp1
[129].
The growing association of mitochondrial fission and neuro-
degeneration has sprouted the interest in compounds capable of
inhibiting mitochondrial fission. Still, while inhibiting mitochondrial
fission may afford protection against acute injury [130], it is becoming
clearer that in the long run, inhibitingfission is not beneficial to neurons
[91,93,131]. Thus, decreasing fission probability by epigenetic modula-
tion, namely with KDAC inhibitors [109], is worth further examination
as an alternative to direct fission inhibition.6. Movement
Mitochondrial movement allows their efficient distribution through-
out the cell. This is particularly relevant in the highly polarized neurons,
where ATP diffusion per se would be inefficient, and thus mitochondria
must travel to supply distant and metabolically demanding sites such
as synapses, nodes of ranvier, and active growth cones [132]. In
mammalian cells, mitochondrial transport relies heavily on microtu-
bules, and motor and adaptor proteins. The kinesin-1 motor family
(KIF5) drives anterograde transport assisted by adaptors such as
Milton orthologues (TRAK1 and TRAK2) linked to mitochondrial rho
(MIRO), an outer membrane RHO family GTPase and Ca2+ sensor.
Syntabulin and FEZ1 are other KIF5-mitochondria adaptors, possibly
allowing directed responses to different physiological signals [131].
Themotor dynein typically drives retrogrademitochondrialmovement,
butmay also be involved in bidirectional transport. Also, presence of both
KIF5 and dynein in the same singlemitochondrion allows for complex bi-
directionalmovement, possibly coordinated bydynactin,which enhances
dynein processivity [131,133]. A key element for microtubule-based
docking of mitochondria in sites of need is syntaphilin, which acts as a
‘static anchor’ for axonal mitochondria thus regulating their mobility
[134].6.1. Microtubule deacetylases and mitochondrial movement
Microtubules are key cytoskeletal elements involved in neuronal mi-
tochondrial trafficking. They are polymers of α/β-tubulin heterodimers
and their functional diversity can be regulated by PTMs [135,136]. Acet-
ylation of α-tubulin at lysine 40 was reported as a specific PTM that en-
hances recruitment of kinesin-1 and dynein/dynactin motor complexes
to microtubules, and stimulates anterograde and retrograde transport
[137,138]. KATs such as the ARD1–NAT1 (ADP-ribosylation factor do-
main protein1 in complex with N-terminal acetyltransferase), and the
Elongator complex, where shown capable of acetylating α-tubulin
[136,139]. Subsequently, αTAT1 was proposed as the major and pos-
sibly the sole α-tubulin K40 acetyltransferase in mammals and nem-
atodes [140]. Conversely, two KDACs, specifically HDAC6 and SIRT2,
were found to interact and deacetylate α-tubulin in vitro and in vivo
[141–143] (Fig. 1; Table 3).
HDAC6 and SIRT2were reported to co-localize along themicrotubule
network and coimmunoprecipitate. Also, silencing of HDAC6 or
SIRT2 alone sufficed to evoke tubulin hyperacetylation [142]. Taken
together with the report that tubulin does not bind HDAC6 or
SIRT2 individually [144], these data supported the hypothesis that
HDAC6 and SIRT2 act interdependently in a protein complex. There
are other studies, however, suggesting they are unlikely binding
partners in vivo given their different expression profiles in brain
cells, with HDAC6 predominating in neurons (esp. Purkinje cells)
and SIRT2 in oligodendrocytes [26,145]. Still, there is also evidence
for SIRT2 expression in hippocampal, cortical and striatal neurons
in vitro [146,147], and a study reporting abundant neuronal expression
of SIRT2, particularly in the adult brain [27]. In such study, authors allude
to a previous observation that tubulin is “not hyperacetylated” in the
brains of HDAC6-deficient mice, and explain it with the possibility that
abundant SIRT2 compensates for lack of HDAC6 [27]. Such allusion, how-
ever, contrasts with the original publication in HDAC6-deficient mice,
where the respective authors state that no significant increase in tubulin
acetylation was found because, in the brain, tubulin is “already highly
acetylated” in wild-type animals, and therefore, HDAC6 inactivation
has no visible impact on acetylation levels [148]. Still, a recent study re-
ports significant increases in α-tubulin K40 acetylation in HDAC6−/−
mice [149].
SIRT2-mediated modulation of mitochondrial trafficking has not
been reported, as far as we could find in the literature. Nevertheless,
there are reports that SIRT2 inhibition does modulate neuronal phys-
iology, being neuroprotective in disease models highly associated
with mitochondrial dysfunction, such as PD and HD. Specifically, SIRT2
inhibition protected against α-synuclein toxicity, decreasing dopami-
nergic neuron death in both in vitro and in vivo (Drosophila) PDmodels,
with the suggestedmechanisms being that increasedα-tubulin acetyla-
tion promotes coalescence of misfolded proteins into larger protective
inclusions [150]. SIRT2 inhibition was also found protective in a striatal
neuron model of HD, by a mechanism involving decreased sterol bio-
synthesis [147]. Such mechanism has been questioned partly due to
contrasting evidence that low sterol/cholesterol levels are associated
with HD neurodegeneration [151]. Thus, further studies are required
to elucidate the putative neuroprotective role of SIRT2 inhibition and
its effects on mitochondrial dynamics.
HDAC6 inhibition promoted both retrograde and anterograde mito-
chondrial movement in hippocampal neurons, together with increased
tubulin acetylation and KIF5-mitochondria association. Further, Glycogen
SynthaseKinase 3β (GSK3β) inhibition: reducedHDAC6phosphorylation
at serine 22; increased tubulin acetylation; and enhanced mitochondrial
movement. Thus, leading to the proposal that GSK3β may regulate
HDAC6 activity by phosphorylation [152]. The implications are that
misregulation of HDAC6, presumably overactivated by GSK3β-mediated
phosphorylation, might underlie impaired mitochondrial transport. Sig-
nificantly, mitochondrial and vesicular trafficking impairment in AD
models was associated with abnormal GSK3β activation [153,154].
Table 3
KDACs and mitochondrial movement or mitophagy.
KDAC isoform Model Activity Modulation Method Main Findings Comments Ref.
HDAC6 Rat primary hippocampal neurons 5 μM Tubastatin A (3h) 
Increased anterograde/retrograde mitochondrial velocity and 
% motility
Reports that HDAC6 inhibition increases α-tubulin  
acetylation, preventing axonal mitochondrial trafficking 
impairment and disrupted morphology caused by Aβ1-42. [157]
Class I, IIa and IIb 0.4 μM TSA (12h) 
2 μM Tubacin (12h) 
1 μM Tubastatin A (12h) 
Class I, IIa and IIb 10 mg/kg TSA (3 weeks in vivo) 
HDAC6 25 mg/kg Tubastatin A (3 weeks in vivo) 
HDAC1 MS-275
HDAC1 inhibition prevents mitochondrial trafficking 
impairment caused by glutamate and TNF-α treatment 
HDAC6 Tubacin
HDAC6 inhibition does not prevent mitochondrial trafficking 
impairment caused by glutamate and TNF-α treatment 
Class I, IIa and IIb 10 μM TSA (2h) 
HDAC6 20 μM Tubacin (2h) 
Primary hippocampal neurons from HDAC6-/- Prevented abnormal mitochondrial trafficking induced by Aβ-
derived diffusible ligands
Hippocampi from APPPS1-21_HDAC6-/- mice Promoted neuronal mitochondrial distribution
Low SIRT1 expression
Unaltered degenerated or collapsed mitochondria number. 
Unaltered LC3b gene expression and LC3-II/LC3-I ratio.
Moderate SIRT1 expression
Increased (2x) degenerated or collapsed mitochondria number. 
Decreased LC3b gene expression and LC3-II/LC3-I ratio.
High SIRT1 expression
Increased (4x) degenerated or collapsed mitochondria number. 
Decreased LC3b gene expression and LC3-II/LC3-I ratio.
SIRT1 Normal human fibroblasts 5 mM Nicotinamide
Induced mitochondrial fragmentation and reduced mass. 
Increased LC3 puncta and LC3-II/I ratio. Decreased Complex V 
levels.
Proposes that nicotinamide optimises mitochondrial 
quality control by promoting fragmentation and 
mitophagy.
[111]
HDAC6 KO Impaired mitophagy
HDAC6 KO followed by reintroduction of 
human HDAC6 Restored mitophagy
[167]
[158]
[159]
[152]
[149]
[186]
Reports that constitutive SIRT1 overexpression in the 
heart impairs mitochondria and reduces cardiac 
function.
DRG neurons from 10 months-old HSPB1S135F 
mice
Mutant HSPB1 mice presented impaired mitochondria 
movement and decreased acetylated-tubulin in 
peripheral nerves. HDAC6 inhibition reverted the 
phenotype.
HDAC6
DRG neurons from 8 months-old HSPB1S135F 
mice
Rat primary cortical and hippocampal neurons
Reports that, in neurons exposed to excitotoxic or 
inflammatory injury, HDAC1 exits the nucleus and binds 
motor proteins impairing mitochondrial trafficking.
HDAC6
Reports that reducing HDAC6 endogenous levels 
improves memory function in AD mice, and suggests 
that this may stem from improved mitochondrial 
trafficking
HDAC6 KO
HDAC6
Parkin-overexpressing mouse fibroblasts 
treated with CCCP for 16h to induce mitophagy
Proposes that the ubiquitin-binding HDAC6 assists 
mitophagy, being recruited to mitochondria 
ubiquitinated by Parkin. HDAC6 was also reported to 
deacetylate cortactin promoting F-actin remodelling 
and autophagosome-lysosome fusion [170].
Rat primary hippocampal neurons Increased axonal mitochondria motility and velocity.
This study shows that HDAC6 inhibition increases 
axonal mitochondria trafficking and reports HDAC6 
activity is modulated by GSK3β. HDAC6 inhibition 
increased motor proteins recruitment to the 
mitochondria.
SIRT1 Mice with heart-specific SIRT1 overexpression
Increased number of motile mitochondria
mice
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linking GSK3β to the trafficking impairment in AD. In fact, evidence sug-
gests that HDAC6 is involved in trafficking abnormalities in several neu-
rodegenerative disorders, as addressed below.6.2. KDAC modulation of trafficking and neurodegeneration
In neurodegenerative diseases such as Huntington and Alzheimer's,
current evidence suggest a beneficial role for HDAC6 inhibition. Indeed,
HD patients' brain samples exhibit decreased tubulin acetylation; and
cellular HDmodels present compromisedmicrotubule-dependent trans-
port, suggesting that transport might be restored by tubulin deacetylase
inhibition [138]. Consistently, selective HDAC6 inhibition with tubacin,
but not HDAC1 inhibition with MS275, increased α-tubulin acetylation
at lysine 40; thus enhancing KIF5 and dynein recruitment to microtu-
bules, and promoting bidirectional transport in striatal cell lines. Further,
KDAC inhibitors capable of inhibiting HDAC6 were shown to enhance
transport-dependent BDNF release in cortical neurons expressing either
wild type or mutant N-terminal huntingtin constructs [138]. Similarly,
decreased α-tubulin acetylation [155] and increased HDAC6 levels
[156] were reported for the AD brain, suggesting a role in abnormal
mitochondrial trafficking in this disease. Also, in hippocampal neurons
challenged with amyloid-β, HDAC6 inhibition with tubastatin A en-
hanced bidirectional mitochondrial motility, rescuing transport and
reducing mitochondrial fragmentation [157]. More recently, HDAC6 de-
letion was reported to improve memory function in AD mice without
affecting amyloid-β plaque load [149]. Significantly, HDAC6 deletion
protected primary neurons from mitochondrial trafficking defects in-
duced by amyloid-β derived diffusible ligands, and enhanced mitochon-
drial distribution in the hippocampi of AD mice [149].
Degeneration of the peripheral nervous system may also benefit
from HDAC6 inhibition, as shown for Charcot–Marie–Tooth disease
models with altered mitochondrial transport. In this context, mice ex-
pressing mutant heat-shock protein HSPB1 presented decreased acet-
ylated tubulin and severe axonal transport deficits. Significantly, DRG
neurons from symptomatic HSPB1S135F mice exhibited decreased mi-
tochondrial number and motility in their neurites. Pharmacological
HDAC6 inhibition in vitro and in vivo rescued the mitochondrial num-
ber and motility phenotype in DRG neurons. Further, in vivo HDAC6
inhibition improved motor performance, together with improved
electrophysiological/histological parameters, suggesting that it might
be a useful therapeutic approach in peripheral neuropathies [158].
In spite of the above evidence, HDAC6 inhibition is unlikely a uni-
versal solution for abnormal axonal transport. Interestingly, evidence
from neuroinflammation models points towards another HDAC – the
normally nuclear-located HDAC1 – as playing a critical role in the onset
of axonal damage and mitochondrial transport abnormalities, not ame-
liorated by HDAC6 inhibition. Neuroinflammatory stimuli (glutamate
plus TNFα) were reported to evoke a Ca2+-dependent nuclear export
of HDAC1 [159]. Interestingly, pan-classical-KDAC inhibition improved
neuronal Ca2+ recovery following glutamate receptor (NMDAR) activa-
tion [160]. Ca2+-dependent nuclear export appears to confer a cytosolic
gain of function to HDAC1, namely, binding α-tubulin and motor pro-
teins (KIF5 and KIF2A), thus impairing their ability to transport cargo
such as mitochondria, leading to localized neurite swelling and degen-
eration [159]. These toxic effects were partly rescued by preventing
HDAC1 nuclear export, or by pharmacological inhibition of HDAC1
with MS275, but not by HDAC6 inhibition with tubacin [159].
Hence, it seems that different KDACs may impair mitochondrial
transport as a function of different pathological triggers, explaining
the opposite findings of inhibiting HDAC6 vs. HDAC1 in models
of HD [138] vs. neuroinflammation [159] (Fig. 1). Still, inhibiting
KDACs for rescuing mitochondrial transport must be balanced
against putative interference with other roles, such as the role of
HDAC6 in mitophagy.7. Mitophagy
The selective degradation of defective mitochondria prevents them
from releasing oxidants and apoptosis triggers, thus being critical for
neuronal health and survival. The mitophagy machinery engulfs and di-
gests small fusion-deficient mitochondria exhibiting sustained depolari-
zation [161]. A key mitophagy regulator is the PINK1–Parkin signaling
pathway. PINK1 acts as Δψm sensor, recruiting Parkin to depolarized mi-
tochondria, thus triggering the mitophagy machinery. Mechanistically,
PINK1 is normally imported into polarized mitochondria and constitu-
tively degraded by PARL (presenilin-associated rhomboid-like protein).
In bioenergetic incompetent mitochondria, however, PINK1 is no longer
degraded and accumulates in the outer membrane where it can recruit
Parkin [162]. Through its E3 ubiquitin ligase activity, Parkin ubiquitinates
mitochondrial proteins like VDAC1 [163] and MIRO (via an interplay
with Pink1 that arrests damaged mitochondria [164,165]), and also
ubiquitinates fusion mediators like mitofusins [166]. Thus, depolarized
mitochondria are rendered fusion-deficient and with a coating that at-
tracts the ubiquitin-binding autophagic components, p62 and HDAC6
[167–169] (Fig. 1).
7.1. KDACs and mitophagy
HDAC6 is reported to play a key role in the quality control autophagy
of protein aggregates and mitochondria [167,170]. HDAC6 has the
capacity to bind polyubiquitinated proteins and also dynein motors,
thus linking target recognition with its transport to aggresomes
[171,172]. Moreover, HDAC6 facilitates aggresome clearance [173,174]
by controlling autophagosome–lysosome fusion [170] (Fig. 1; Table 3).
The HDAC6 ubiquitin- and dynein-binding motifs are distinct
from the tubulin deacetylase domain that is selectively targeted by
HDAC6 inhibitors [175], which were neuroprotective in several dis-
ease models [138,157,158]. Nevertheless, there is evidence that a
functional HDAC6 deacetylase domain is required for aggresome
formation, autophagosome–lysosome fusion and autophagic turn-
over [170,172–174]. Thus, although HDAC6 inhibition enhances mi-
tochondrial and vesicle trafficking, it may hinder mitophagy as well
as the turnover of misfolded proteins. Still, when reduced axonal
trafficking is the main problem for a given disease state, HDAC6 inhi-
bition might be beneficial if compensatory mechanisms allow for ad-
equate protein and mitochondria turnover.
SIRT1may partly compensate for HDAC6 inhibition. Autophagosome–
lysosome fusion requires cytosolic HDAC6 catalytic activity to deacetylate
cortactin, whichmediates the necessary F-actin remodeling [170]. Mean-
ingfully, in the adult brain, SIRT1 is predominantly located in the cytosol
[22], thus being in a position to interact with cortactin. In fact, HDAC6
and SIRT1 were both shown to bind and deacetylate cortactin indepen-
dently, but may alsowork cooperatively or competitively, with their rela-
tive dominance being cell type dependent [176] (Fig. 1). Further, although
HDAC6 knockout mice are reported to develop ubiquitin-positive brain
aggregates [170], they are also described as developing normally, being
fertile and viable, without obvious brain and spinal cord abnormalities
[148]. Thus, it is conceivable that increased activity of SIRT1 might com-
pensate for the consequences of HDAC6 knockout/inhibition on cortactin
acetylation, and consequently on autophagosome–lysosome fusion.
SIRT1 activationwas associatedwithmitophagy induction in human
fibroblasts. Indeed, treatment with SIRT1 activators or with nicotin-
amide (5 mM — a concentration that converts to NAD+ and activates
SIRT1 [112])was reported to acceleratemitophagy at least in part by in-
ducing mitochondrial fragmentation. Consistently with quality control
mitophagy activation, treated cells exhibited a decreasedmitochondrial
mass but increased Δψm; together with increased levels of the
autophagosomal marker LC3-II, and higher number of mitochondria-
associated LC3 puncta and lysosomes [111,112; but see 186]. While
the exact mechanisms downstream of SIRT1 activation remain uncer-
tain, findings are consistent with the ongoing degradation of small
1355P. Guedes-Dias, J.M.A. Oliveira / Biochimica et Biophysica Acta 1832 (2013) 1345–1359depolarizedmitochondria, which are preferential targets for mitophagy
[161].
Further studies are required to clarify the interplay between HDAC6
and SIRT1 in the regulation of mitophagy. While HDAC6 modulation
may have therapeutic potential in neurodegeneration [177], the effects
of HDAC6 inhibition on axonal trafficking must be balanced against the
fact that misfolded protein aggregates are a hallmark of several neuro-
degenerative diseases [178]. Therefore, HDAC6 inhibition aimed at pro-
moting neuronal mitochondrial trafficking should be further explored
to test for implications in autophagolysosome formation and clearance
in neurons.
7.2. Mitophagy in neurodegeneration
Parkinson's disease has taken the lead in the research onmitophagy
impairment, partly due to the links between the PINK1–Parkin pathway
and familial forms of this neurodegenerative disorder [179]. Wild-type
Parkin is selectively recruited to dysfunctional mitochondria and pro-
motes their autophagy [180]. Parkin recruitment depends on functional
PINK1, and loss of function mutations in PINK1 or Parkin can block
mitophagy [163]. Thus, PD neurodegeneration may at least partly stem
from impairment in selective mitochondrial clearance, leading to the ac-
cumulation of dysfunctional organelles.
In Alzheimer's disease brains, the area of intact mitochondria was
found decreased in vulnerable neurons, together with increased mtDNA
and proteins in vacuoles associatedwith lipofuscin. This increase inmito-
chondrial degradation products suggested either increased mitophagy
or decreased proteolytic turnover [76]. Indeed, it has been proposed
that AD mitochondria are susceptible to increased autophagic degrada-
tion [181,182], but it is still uncertain whether increased mitophagy is a
protective response or contributing to pathology, possibly in a synergistic
manner with dysfunctional fission–fusion dynamics [183]. Interestingly,
increased Parkin expression in AD mice was shown to decrease intracel-
lular amyloid-β levels and extracellular plaque deposition, while also
promoting autophagic clearance of defective mitochondria [184].
Huntington's disease cellular models were reported to exhibit de-
fects in cargo recognition by autophagic vacuoles, preferentially af-
fecting organelle sequestration, and leading to the accumulation of
abnormal mitochondria. Further, an abnormal interaction between
mutant huntingtin and the autophagic adaptor p62 was proposed to
cause the cargo recognition failure [185]. Interestingly, it has been
reported that HDAC6 is required for efficient autophagic degradation
of aggregated huntingtin [173]. Thus, the modulation of HDAC6 activ-
ity might be an interesting strategy to improve the clearance of both
mutant huntingtin and abnormal mitochondria in HD.
8. Concluding remarks
Lysine deacetylases are emerging therapeutic targets in neuro-
degeneration. Current evidence suggests that their modulation, namely
with epigenetic drugs such as KDAC inhibitors, may assist correction of
abnormal mitochondrial dynamics in neurodegenerative diseases. The
enhancement of mitochondrial biogenesis, movement, quality control
mitophagy, and the restoration of fission–fusion balance have all been
proposed as neuroprotective strategies. Concerning mitochondrial bio-
genesis, it is predominantly reported enhanced by SIRT1 activation. Still,
recent findings suggest caution in interpreting data generated with un-
certain SIRT1 activators. Future studies should help clarify the SIRT1-
biogenesis connection and provide further mechanistic data for the
role of SIRT3 and other KDACs in this process. Excessive mitochondrial
fission is consistently reported formultiple neurodegenerative diseases,
but arresting this crucial physiological event is also detrimental to neu-
rons. Thus, decreasing fission probability with KDAC inhibitors is worth
further examination as an alternative to direct fission inhibition. Abnor-
mal mitochondrial transport has been associated with both HDAC6 and
HDAC1 activities depending on the pathological trigger. In differentneurodegenerative disease models, HDAC6 inhibition was shown to
rescue trafficking abnormalities. Still, given the ubiquitin-binding and
autophagosome–lysosome fusion promoting activities of HDAC6, the
consequences of HDAC6 inhibition upon autophagy and clearance of
misfolded proteins require further exploration. Conceivably, when re-
duced axonal trafficking is the main problem for a given disease state,
HDAC6 inhibition might be beneficial if compensatory mechanisms
allow for adequate autophagy and protein turnover.Acknowledgements
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